JAMA · 1963 · 27 citations · 7 references
PharmacyPharmacologyPharmacotherapyCardiovascular PharmacotherapyClinical PharmacologyPharmacodynamicsBlood Pressure ControlBlood Pressure ManagementDiuretic TherapyHypertension ControlHypertension ManagementHypertension PharmacotherapyAntihypertensive Drug TherapyAntihypertensive PharmacologyAntihypertensive TreatmentBlood PressurePharmacological Interaction In HypertensionPotassium-sparing Diuretic EffectsPotassium-sparing DiureticsTherapeutic Trials
Triamterene, a new potassium-sparing pteridine diuretic was found to have a weaker saluretic effect than the benzothiadiazines in nonedematous patients. However, a combination of 50 mg of triamterene plus 25 mg of hydrochlorothiazide, while continuing to prevent potassium loss, exhibited saluretic potency equivalent to 50 mg of hydrochlorothiazide alone. In 32 hypertensive outpatients, crossover therapeutic trials revealed that the combination just mentioned was as effective in controlling blood pressure as full doses of hydrochlorothiazide alone, whereas hypokalemia was prevented. No toxic effects, attributable to triamterene, were detected during the course of these studies.
7
John G. Gibson, William A. Evans · Journal of Clinical Investigation · 1937 · 223 citations · Full text
Triamterene, A New Natruretic Agent
Archer P. Crosley · Annals of Internal Medicine · 1962 · 54 citations